重组FSH控制下超促排卵和宫腔内人工受精治疗不育患者-202周期

目的观察重组基因的促卵泡生长激素(recombinant follicle stimulating hormone,r-FSH)在非器质原因与非排卵障碍的不育患者中进行控制下超促排卵和宫腔内人工受精的疗效.方法以88名在墨尔本Monash医院确诊的非器质原因与非排卵障碍的不育患者为研究对象,给予r-FSH超促排卵,期望最多得到3个成熟卵泡,注射人绒毛膜促性腺激素(human chorionic gonadotropin,HCG)36 h时,给予宫腔内人工受精.共接受202个周期的治疗.结果周期排卵率95.7%,无排卵率4.3%,周期取消率7.4%,周期妊娠率11.6%,双胎发生率15%,每名患者的妊娠率为22.7%.妊娠周期组与非妊娠周期组相比,在年龄、体重指数、周期治疗天数、成熟卵泡数、内膜厚度、治疗周期等观察指标方面差异无显著性(P＞0.05),但在不孕时间上差异有显著性(P＜0.05),妊娠周期组的不孕时间小于非妊娠周期组.结论对于非器质性原因与非排卵障碍的不育患者,应用超排卵治疗和宫腔内人工受精不失为一种相对廉价、有一定成效的、安全的助孕方法.

Superovulation and intrauterine insemination in treatment of idiopathic infertility in 202 cycles

OBJECTIVE: To evaluate the effect of superovulation with recombinant follicle stimulating hormone (r-FSH) therapy and intrauterine insemination in the treatment of idiopathic infertility. METHODS: Superovulation with r-FSH therapy and intrauterine insemination were used in 202 cycles of 88 couples in the Department of Obstetrics and Gynecology of Monash Medical Centre. RESULTS: The per cycle ovulation rate and in-ovulation rate were 95.7% and 4.3% respectively, and the per cycle pregnancy rate was 11.6% with no cases of hyperstimulation. The cancelling rate was 7.4% because of the development of multiple follicles. The overall cumulative conception rate was 22.7% per patient, with 15% of twin pregnancies. There were no differences between pregnancy group and non-pregnancy group in age, BMI, treatment days, number of mature follicles, endometrial thickness and number of treatment cycles. The only significant parameter observed between the two groups was infertility time (P < 0.05), which was longer in non-pregnancy group [(30.52 +/- 13.08) months] than in pregnancy group [(24.25 +/- 6.45) months]. CONCLUSIONS: Superovulation and intrauterine insemination is a safe and more cost-effective method in treatment of idiopathic infertility.